SCHEMBL3104904

SCHEMBL3104904

COc1cccc(Cc2nc(CN3CC=CCC3)nn2-c2ccc(S(N)(=O)=O)cc2F)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 1/20 0.40
HTR6 P50406 1/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
LMNA P02545 1/20 0.35
HTT P42858 1/20 0.35
ALOX15 P16050 1/20 0.35
TSHR P16473 1/20 0.35
CA1 P00915 6/20 0.34
CA2 P00918 6/20 0.34
CA9 Q16790 6/20 0.34
CA12 O43570 3/20 0.34
CASP1 P29466 1/20 0.34
CASP4 P49662 1/20 0.34
CASP5 P51878 1/20 0.34
ALDH1A1 P00352 4/20 0.33
POLB P06746 2/20 0.33
CA7 P43166 2/20 0.33
CA14 Q9ULX7 2/20 0.33
GAA P10253 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3108949 0.91 PTGS2 (0.45) PTGS2CA1CA2CA9CA12
SCHEMBL3105243 0.90 CA2 (0.34) PTGS2HTR6LMNAHTTCA1
SCHEMBL3100267 0.89 CA1 (0.37) PTGS2CA1CA2CA9CA12
SCHEMBL3109234 0.88 CA1 (0.36) PTGS2HTR6CA1CA2CA9
SCHEMBL13099902 0.86 SOS1 (0.35) PTGS2CA1CA2CA9CA12
SCHEMBL13099939 0.86 ADORA2A (0.37) PTGS2CA1CA2CA9CA12
SCHEMBL3115563 0.85 CA2 (0.40) PTGS2CA1CA2CA9CA12
SCHEMBL13099903 0.85 CA2 (0.41) PTGS2MEN1KMT2ACA1CA2
SCHEMBL3113567 0.85 PTGS2 (0.37) PTGS2HTR6KMT2ALMNACA1
SCHEMBL3104772 0.84 CA1 (0.40) PTGS2HTR6MEN1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100256357-A1 HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE AGOURON PHARMACEUTICALS, INC. 2010-10-07 US disclosed
US-20100256357-A1 HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE AGOURON PHARMACEUTICALS, INC. 2010-10-07 US disclosed
US-20100256357-A1 HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE AGOURON PHARMACEUTICALS, INC. 2010-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256357-A1 HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE CA2, CA7, CA9 PTGS2 47/4885HTR6 3760/4885MEN1 2036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.